IPHA — Innate Pharma S.A.

Innate Pharma (IPHA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue and Income: Total revenue and other income for 2025 amounted to EUR 9 million, including EUR 2.8 million from licensing agreements and EUR 6.2 million from government funding for research.
• Operating Expenses: Total operating expenses were EUR 63 million, with 73% allocated to R&D (EUR 43.6 million), reflecting a 16% decrease year-over-year due to maturing studies and reduced indirect costs.
• Cash Position: As of December 31, 2025, cash and equivalents stood at EUR 44.8 million, providing funding visibility until Q3 2026.

2. Strategic Updates and Business Highlights

• Pipeline Focus: Innate Pharma is concentrating on three high-value clinical assets: lacutamab, IPH4502, and monalizumab. The company has streamlined operations to enhance decision-making and capital allocation.
• Lacutamab: Received FDA clearance for the TELLOMAK-3 Phase III trial in cutaneous T-cell lymphoma (CTCL), expected to start in H2 2026. The drug has Breakthrough Therapy Designation and is positioned for potential accelerated approval.
• IPH4502: Progressing in a Phase I trial, showing early signs of antitumor activity in heavily pretreated patients, particularly in urothelial cancer. The design aims to address limitations of existing therapies and expand into broader tumor types.
• Monalizumab: The PACIFIC-9 Phase III trial in non-small cell lung cancer has completed enrollment, with data expected in H2 2026.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Multiple key milestones are anticipated in 2026, including the initiation of the TELLOMAK-3 study and data readouts for IPH4502 and monalizumab.
• Commercial Strategy: For lacutamab, a focused commercial approach is planned, targeting specialized academic centers. Initial market potential is estimated at up to EUR 150 million for Sezary syndrome, expanding to over EUR 500 million with Mycosis Fungoides.

4. Challenges and Points of Concern

• Restructuring Impact: The company has implemented a redundancy plan to streamline operations, which may affect employee morale and operational continuity.
• Revenue Decline: The revenue from collaboration agreements has dropped significantly, reflecting the transition of projects to AstraZeneca, which may impact future income streams.
• Competitive Landscape: The ADC market is competitive, with ongoing developments from other companies that could pose risks to IPH4502's positioning.

5. Notable Q&A Insights

• IPH4502 Interest: There is significant interest in the IPH4502 program, with preliminary antitumor activity observed in multiple tumor types. The company is focusing on the post-PADCEV setting, which is currently underserved.
• Lacutamab Partnerships: Discussions for potential partnerships or financing structures are ongoing, with a focus on maximizing shareholder value while ensuring timely market entry.
• MATISSE Trial Presentation: The interim data from the MATISSE trial is expected to provide insights into the efficacy of IPH5201 in combination with durvalumab, with promising early results noted in prior studies.

Overall, Innate Pharma is strategically positioning itself for growth with a focused pipeline while navigating challenges related to restructuring and competitive pressures.